Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs
Autore:
Wade, TV; Schneider, JS;
Indirizzi:
Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA Thomas Jefferson Univ Philadelphia PA USA 19107 hiladelphia, PA 19107 USA
Titolo Testata:
JOURNAL OF NEUROSCIENCE
fascicolo: 13, volume: 21, anno: 2001,
pagine: 4901 - 4907
SICI:
0270-6474(20010701)21:13<4901:EOSPMI>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
MESSENGER-RNA LEVELS; GENE-EXPRESSION; BASAL GANGLIA; DOPAMINE TRANSPORTER; SUBSTANCE-P; CAUDATE-PUTAMEN; MPTP; PREPROENKEPHALIN; SYSTEMS; DISEASE;
Keywords:
preprotachykinin; striatum; parkinsonism; dopamine; MPTP; monkey;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Schneider, JS Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,521 JAH, Philadelphia, PA 19107 USA Thomas Jefferson Univ 1020 Locust St,521 JAH Philadelphia PA USA 19107
Citazione:
T.V. Wade e J.S. Schneider, "Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs", J NEUROSC, 21(13), 2001, pp. 4901-4907

Abstract

Striatal preprotachykinin (PPT) gene expression and [H-3] mazindol bindingwere examined in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Some animals (n = 5) became moderately to severely parkinsonian after receiving large doses of MPTP over 9-30 d and remained symptomatic for a relatively short time (3 weeks to 3 months; acutely symptomatic group). A second group of animals (n = 5) received low doses of MPTP (1.5-12 months), developed cognitive impairments but displayed no gross motor deficits (asymptomatic group), and were killed 3-12 months after their final doseof MPTP. Other animals became moderately to severely parkinsonian after receiving escalating doses of MPTP (>6 months; n = 4) or high doses of MPTP (<1 month; n = 1) and remained symptomatic for 2.5-5.75 years (chronically symptomatic group). All MPTP-treated animals had extensive losses of [H-3] mazindol binding in dorsal striatal sensorimotor regions with asymptomatic animals generally having a lesser degree of damage. However, PPT mRNA levelsdiffered sharply among treatment groups. Symptomatic animals (acutely and chronically parkinsonian) had significantly decreased PPT mRNA levels in most striatal regions. In asymptomatic animals, PPT mRNA expression was not significantly different from that measured in control animals, despite decreases in [H-3] mazindol binding in some striatal regions of similar magnitude to those observed in symptomatic animals. These observations suggest thatPPT gene expression may be directly related to expression of parkinsonian motor symptomatology regardless of duration of MPTP exposure, duration of the parkinsonism, or extent of dopamine denervation. These results imply that the direct striatal output circuit may have a greater contribution to expression of parkinsonian symptomatology than proposed previously.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/06/19 alle ore 17:00:48